GlassScriptPhysician profile
Jency P Vathikulam
NPI 1790122562
$3,578.06
in general payments reported to CMS, 2019-2025
37 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $993 · 2021: $557 · 2022: $244 · 2023: $424 · 2024: $310 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,120.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.16 | 2021-2024 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $377.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $268.20 | 2019-2023 | Breztri |
| Abbott Laboratories | $214.43 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $202.26 | 2019-2021 | |
| Amarin Pharma, INC. | $181.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.00 | 2019-2024 | Xifaxan |
| Amgen INC. | $174.88 | 2019-2025 | Repatha, Evenity, Prolia |
| Pfizer INC. | $158.52 | 2019-2025 | |
| Lilly USA, LLC | $127.21 | 2020-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.62 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $116.40 | 2019-2023 | |
| Glaxosmithkline, LLC. | $105.30 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Allergan, INC. | $78.85 | 2019-2020 | |
| Genentech USA, INC. | $72.63 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jency Vathikulam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.